Navigation Links
Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody for the Treatment of Autoimmune Diseases
Date:10/21/2011

MONROVIA, Calif., Oct. 21, 2011 /PRNewswire/ -- Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, announced today the initiation of a Phase 1 clinical trial of XmAb®5871, the company's therapeutic antibody for the treatment of autoimmune diseases. XmAb5871 uses a novel dual-targeted approach to potently suppress autoimmune disorders that may avoid some of the side effects seen with other therapeutic antibodies that modulate immune response. The advancement of XmAb5871 into clinical stage testing demonstrates the broad potential of Xencor's antibody engineering technology in immune and inflammatory diseases in addition to oncology.

Earlier this year, Amgen and Xencor entered into an option agreement to develop XmAb5871. Under the terms of the agreement, Amgen has the option to an exclusive worldwide license following the completion of a pre-defined Phase 2 study. Xencor will lead all clinical development until that time.

"XmAb5871 is Xencor's first therapeutic antibody for immune disorders, and is the fifth XmAb product to enter clinical testing," said Bassil Dahiyat, Ph.D., president and CEO of Xencor. "Xencor's robust product pipeline in oncology, and now autoimmune disease, is evidence of the broad applicability of our XmAb technology across multiple therapeutic areas."

XmAb5871 is a humanized monoclonal antibody that uses a uniquely selective dual-targeting mechanism for B cell inhibition by targeting the antigen CD19 and co-engaging CD32b (FcγRIIb), thereby suppressing autoimmune response. Preclinical studies published in the Journal of Immunology showed that XmAb5871 potently suppresses autoimmune response in humanized mouse models of systemic lupus erythematosus (SLE), without the depletion of B cells. This suggests that XmAb5871 may be an effective immunosuppressant in multiple indications, including SLE and rheumatoid arthrit
'/>"/>

SOURCE Xencor, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Finland initiates European biomedical research infrastructures construction with $6.7 million for 2011
2. Rosetta Genomics Initiates Closing of Private Placement
3. Phase III data show efficacy/safety of iclaprim in patients with complicated skin infections
4. Positive results in Phase 2 trial of treatment of C-difficile-associated diarrhea
5. NIH grants Phylonix Phase II SBIR to develop high-throughput in vivo zebrafish assays
6. Biolex presents Locteron US Phase 2a hepatitis C data at EASL
7. Cantabrian cornice has experienced seven cooling and warming phases over past 41,000 years
8. Resolvyx announces positive data -- Phase 2 trial of resolvin RX-10045 for dry eye syndrome
9. Scientists seek new emphases in Arctic climate change research
10. NIH funds new phase of high school-university research partnership
11. Registration Opens for Next Testing Phase of IEEE Certified Biometrics Professional Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 7, 2014 ... Market Research "Electronic Access Control Systems Market Global Forecast, ... 2019," the global Electronic Access Control systems market was ... expected to grow at a CAGR of 12.6% from ... USD 31,187.8 million in 2019. Browse the ...
(Date:7/10/2014)... The genus Axinaea belongs to the large, mainly ... the ca. 5000 species in the family rely on bees ... pollinated by other insects or vertebrates. The flowers of ... twenty flowers and the petals of the different species are ... stand out based on the contrasting colours of their bulbous ...
(Date:7/10/2014)... or even improve the state of fisheries resources ... the Mediterranean has deteriorated over the past 20 ... species reported in the Cell Press journal ... for stringent monitoring of Mediterranean fishing activities, better ... in Mediterranean waters. , Their data show that ...
Breaking Biology News(10 mins):Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5Novel type of bird pollination mechanism discovered in South America 2Mediterranean fish stocks show steady decline 2
... be enough to cool a hot temper, at least for a ... people who drank a glass of lemonade sweetened with sugar acted ... people who consumed lemonade with a sugar substitute. Researchers believe ... found in the bloodstream that provides energy for the brain. ...
... shows that anti-microbial medications are a common cause of ... (ALF), with women and minorities disproportionately affected. While ALF ... is unlikely; however liver transplantation offers an excellent survival ... published in the December issue of Hepatology , ...
... Washington, D.C. - U.S Energy Secretary Steven Chu today ... time to 57 innovative research projects - using computer ... would be impossible or impractical in the natural world. ... equal to 135,000 quad-core laptops, the research could, for ...
Cached Biology News:Researchers find link between sugar, diabetes and aggression 2Researchers find link between sugar, diabetes and aggression 3Researchers find link between sugar, diabetes and aggression 4Study finds anti-microbials a common cause of drug-induced liver injury and failure 2Could 135,000 laptops help solve the energy challenge? 2Could 135,000 laptops help solve the energy challenge? 3Could 135,000 laptops help solve the energy challenge? 4
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... 2014 Robert Harman, DVM, Founder and CEO ... proud to announce the relaunch of his highly informative blog, ... series called “ What are Stem Cells ?” Dr. ... straightforward foundation in the basics of stem cell therapy so ... right type of treatment when considering regenerative medicine. , A ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded ... with a second treatment cup to help prevent and smooth ... is thinner on the edges for a softer contact with ... uneven surfaces on the face, neck and décolleté. Choose to ... areas such as the cheeks and neck, or opt for ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... Leader in, Animal Health and Strengthens Product Pipeline, Adding ... ... Projects, KENILWORTH, N.J., Nov. 19 Schering-Plough,Corporation (NYSE: ... BioSciences N.V., creating a stronger combined,company with broader human and animal ...
... discovery of a new way to manipulate light a million ... Science this week. , Using a special hollow-core photonic ... has opened the door to what could prove to be ... and trapping. , The team, led by Dr Fetah Benabid, ...
... The Committee for,Medicinal Products for Human Use ... (EMEA), granted Abbott (NYSE: ABT ) a ... treatment,of moderate to severe plaque psoriasis. Psoriasis will ... is a non-contagious, chronic autoimmune disease that causes,the ...
Cached Biology Technology:Schering-Plough Completes Acquisition of Organon BioSciences 2Schering-Plough Completes Acquisition of Organon BioSciences 3Schering-Plough Completes Acquisition of Organon BioSciences 4Schering-Plough Completes Acquisition of Organon BioSciences 5Discovery of a new way to manipulate light a million times more efficiently 2Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 2Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 3Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 4Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 5Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 6Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 7Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 8
... Edited by John M. Walker (1996) ... successful analytical techniques for studying proteins ... protocol contains detailed, step-by-step instruction, timesaving ... and comprehensive lists of reagents and ...
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
Human/Mouse/Rat Keap1 MAb (Clone 333116) Protein Family: Transcription Factor Regulators...
... 4503277 Accession Number: NP_001912.1 ... the nucleotide substrate for thymidylate synthetase. ... O = dUMP + NH 3 ... the Diseases: Benign Tumor; Leukemia; Escherichia ...
Biology Products: